Therapeutic Peptides in Oncology - Favorable Conditions But Where to Commercialize?BioSeeker Group ABMay 28, 2009 373 Pages - SKU: BIOS2275865 |
|
Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
5/11/2012 | published by: Kalorama Information
The drug discovery process is long, arduous and costly, which has driven outsourcing in this field. The first phase is discovery of a lead compound, a molecule that affects biological function by binding to a
|
more...
|
$3,995.00
|
|
541711 Research and Development In Biotechnology: State Industry Market Evaluator
6/1/2012 | published by: BizMiner
This State Industry Market Evaluator reports on industry trends broken out for each US state. Each state sub-report is comprised of eight pages of data. Statistics are displayed for 2008-2009-2010 and 2011q2 for these measures:
|
more...
|
$699.00
|
|
World Market for Prescription Dermatological Drugs, 8th Edition (Antiacne, Antiaging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments)
3/1/2012 | published by: Kalorama Information
This Kalorama Information report, The Worldwide Market for Prescription Dermatological Drugs represents the eighth time that Kalorama has detailed the various categories of prescription dermatological drugs, describing the global market and identifying major market factors
|
more...
|
$3,995.00
|
|
Triple Analysis: Cancer Vaccines, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Cancer Vaccines and Protein Kinase Inhibitors and by the compound strategy of Antibodies. Each of these three individual parts is
|
more...
|
$5,175.00
|
|
Triple Analysis: Cancer Vaccines, Protein Kinase Inhibitors and Peptides
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Cancer Vaccines and Protein Kinase Inhibitors and by the compound strategy of Peptides. Each of these three individual parts is
|
more...
|
$5,175.00
|
|
Triple Analysis: Colorectal Cancer, Cancer Vaccines and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in Colorectal Cancer and by the two mechanism/target/effect areas of Cancer Vaccines and Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to
|
more...
|
$5,175.00
|
|
Triple Analysis: Colorectal Cancer, Leukemia and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Leukemia and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria
|
more...
|
$5,175.00
|
|
Triple Analysis: Colorectal Cancer, Lung Cancer and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Lung Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized
|
more...
|
$5,175.00
|
|
Triple Analysis: Colorectal Cancer, Melanoma and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Melanoma and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria
|
more...
|
$5,175.00
|
|
Triple Analysis: Colorectal Cancer, Prostate Cancer and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Prostate Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized
|
more...
|
$5,175.00
|
Related Markets
- Biotechnology
- Emerging Technology
- Research & Development
- Pharmaceuticals
- Drug Discovery
- Therapeutic Area
- Oncology/Hematology
Oncology/Hematology Reports
- Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Peptides
- Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Antibodies
- Triple Analysis: Prostate Cancer, Cancer Vaccines and Protein Kinase Inhibitors
- Triple Analysis: Prostate Cancer, Apoptosis and Protein Kinase Inhibitors
- Triple Analysis: Prostate Cancer, Angiogenesis and Protein Kinase Inhibitors

